The EMA will study the feasibility of vaccination of children aged 5-11 years

As noted in the agency, the data obtained indicate that with the spread of the “delta” variant, the number of cases of hospitalization of adolescents increases sharply.

The European Medicines Agency (EMA) intends to study the feasibility of vaccination against coronavirus in children aged 5-11 years. This was announced on Thursday at a briefing by the head of the EMA Department for health threats and vaccination strategy, Marco Cavaleri.

According to him, the data obtained from the United States indicate that with the spread of the “delta” variant, the number of cases of hospitalization of adolescents who are not vaccinated is sharply increasing. “Two mRNA vaccines approved in the EU are allowed for use among people over 12 years of age,” the expert noted. “It is believed that the benefits of using these vaccines among adolescents outweigh the risks.”

“For children under the age of 12, we expect to receive data on at least some vaccines during the fall to understand whether the benefits of using them outweigh the risks among children aged 5-11 years,” Cavaleri said. “We will study this issue.”

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Watch more posts:
Author: Ivan Maltsev
The study of political and social problems of different countries of the world. Analysis of large companies on the world market. Observing world leaders in the political arena.
Function: Chief-Editor
Ivan Maltsev

Spelling error report

The following text will be sent to our editors: